All In Biotech

Drug Trial Radar · NCT02667444

P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne

A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily SB204 and Vehicle Gel in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,330

Actual

Start

Feb 19, 2016

Primary completion

Dec 2016

Study completion Dec 9, 2016

Sponsor

Lead sponsor
Novan, Inc.Industry
Sponsor type
Industry
Collaborators
Chiltern International Inc.
First posted
Jan 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 9 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.

Conditions

  • Acne Vulgaris

Interventions

  • SB204 4%Drug

    Applied topically once daily

  • Vehicle GelDrug

    Applied topically one daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Inflammatory Lesion CountsTime frame: Baseline and Week 12
  2. Absolute Change From Baseline in Non-inflammatory Lesion CountsTime frame: Baseline and Week 12
  3. Proportion of Subjects With Investigator Global Assessment (IGA) Success at Week 12Time frame: Week 12

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • CIL #214

    Birmingham, Alabama

  • CIL #218

    Mobile, Alabama

  • CIL #189

    Phoenix, Arizona

  • CIL #139

    Cerritos, California

  • CIL #216

    Chula Vista, California

  • CIL #181

    Encino, California

  • CIL #174

    Huntington Beach, California

  • CIL #213

    La Mesa, California

  • CIL #190

    Sacramento, California

  • CIL #111

    San Diego, California

  • CIL #195

    Santa Ana, California

  • CIL #119

    Santa Monica, California

  • CIL #158

    Bradenton, Florida

  • CIL #208

    Hialeah, Florida

  • CIL #142

    Miami, Florida

  • CIL #170

    Miami Lakes, Florida

  • CIL #204

    Miami Springs, Florida

  • CIL #185

    Ormond Beach, Florida

  • CIL #110

    Pinellas Park, Florida

  • CIL #227

    Sanford, Florida

  • CIL #176

    St. Petersburg, Florida

  • CIL #152

    Tampa, Florida

  • CIL #144

    Tampa, Florida

  • CIL #116

    Newnan, Georgia

  • CIL #143

    Savannah, Georgia

  • CIL #175

    New Albany, Indiana

  • CIL #191

    Overland Park, Kansas

  • CIL #228

    Louisville, Kentucky

  • CIL #194

    Richmond, Kentucky

  • CIL #219

    Monroe, Louisiana

  • CIL #145

    Boston, Massachusetts

  • CIL #155

    Bay City, Michigan

  • CIL #220

    St Louis, Missouri

  • CIL #148

    Norfolk, Nebraska

  • CIL #206

    Omaha, Nebraska

  • CIL #202

    Morristown, New Jersey

  • CIL #197

    New York, New York

  • CIL #196

    Charlotte, North Carolina

  • CIL #192

    Raleigh, North Carolina

  • CIL #221

    Salisbury, North Carolina

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.